Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
125 people get PRX articles and Market Currents by email alert.
Get email alerts on PRX »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
PR Newswire (Sep 28, 2012)
-
3 Drugmakers Trading Near Highs With Strong Receivable TrendsKapitall • Thu, Aug 16, 2012 -
PR Newswire (Aug 2, 2012)
-
-
-
PR Newswire (Jul 16, 2012)
-
PR Newswire (Jul 13, 2012)
-
-
PR Newswire (Jul 9, 2012)
-
-
7 Rallying Healthcare Stocks Undervalued By EPS TrendsKapitall • Wed, May 9, 2012
-
PR Newswire (May 8, 2012)
-
Stifel Nicolaus Sees An Opportunity In Horizon Pharma SharesBen Yoffe • Tue, May 8, 2012
-
-
PR Newswire (Apr 19, 2012)
-
Valeant: Ready To Move On Increased R&DStock Croc • Thu, Apr 12, 2012 -
-
PR Newswire (Apr 9, 2012)
To learn more about Seeking Alpha Pro, click here.
-
3 Drugmakers Trading Near Highs With Strong Receivable TrendsKapitall • Thu, Aug 16, 2012
-
-
-
-
7 Rallying Healthcare Stocks Undervalued By EPS TrendsKapitall • Wed, May 9, 2012
-
Stifel Nicolaus Sees An Opportunity In Horizon Pharma SharesBen Yoffe • Tue, May 8, 2012
-
-
Valeant: Ready To Move On Increased R&DStock Croc • Thu, Apr 12, 2012
-
-
Winning Long-Term Plays In Generic DrugsValueMax • Thu, Apr 5, 2012
-
-
-
-
-
Upside Winners Abbott, Johnson & Johnson Each Worth Over $80Takeover Analyst • Thu, Jan 5, 2012 -
-
Greenblatt's Magic Formula Portfolio Quarterly UpdateValue Research • Wed, Nov 30, 2011
-
-
Emisphere: Crown Jewel In Oral B12Josh Franklin • Fri, Oct 7, 2011 -
-
Par Pharmaceutical Companies Inc Q4 2008 Earnings Call TranscriptTue, Mar 3, 2009
-
Par Pharmaceutical Companies Inc. Q3 2008 Earnings Call TranscriptFri, Nov 7, 2008
-
Par Pharmaceutical Companies, Inc. Q2 2008 Earnings Call TranscriptFri, Aug 8, 2008
-
Par Pharmaceutical Companies Inc. Q1 2008 Earnings Call TranscriptMon, Jun 2, 2008
-
Par Pharmaceutical Companies Inc. Q1 2008 Earnings Call TranscriptFri, May 30, 2008
-
Par Pharmaceuticals Inc Q4 2007 Earnings Call TranscriptMon, Mar 24, 2008
-
PR Newswire (Sep 28, 2012)
-
PR Newswire (Aug 2, 2012)
-
at CNBC.com (Jul 16, 2012)
-
at MarketWatch.com (Jul 16, 2012)
-
at CNBC.com (Jul 16, 2012)
-
at CNBC.com (Jul 16, 2012)
-
at CNBC.com (Jul 16, 2012)
-
PR Newswire (Jul 16, 2012)
-
PR Newswire (Jul 13, 2012)
-
PR Newswire (Jul 9, 2012)
-
PR Newswire (May 8, 2012)
-
PR Newswire (Apr 19, 2012)
-
PR Newswire (Apr 9, 2012)
-
PR Newswire (Apr 6, 2012)
-
at MarketWatch.com (Feb 28, 2012)
-
PR Newswire (Dec 5, 2011)
-
at MarketWatch.com (Feb 24, 2011)
-
at MarketWatch.com (Dec 7, 2010)
-
at MarketWatch.com (Aug 2, 2010)
PRX vs. ETF Alternatives
Company Description
Par Pharmaceutical Companies, Inc., incorporated in 1978 as Par Pharmaceutical, Inc., is a Delaware holding company that, principally through its wholly owned operating subsidiary, Par Pharmaceutical, Inc., is in the business of developing, licensing, manufacturing and distributing generic and... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Monday, July 16, 2012, 8:24 AM TPG agrees to acquire Par Pharmaceutical (PRX) for $1.9B, or $50/share, which represents a 37% premium over Par's closing price on Friday. Shares +36% premarket. (PR) Comment! [Healthcare, Breaking News, On the Move, M&A]
-
Asif Suria
Par Pharmaceutical Companies Enters Into Definitive Agreement To Be Acquired By TPG for $50.00 per share in cash $PRX http://bit.ly/MzNM8g - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
MagicDiligence
Par Pharma - Buried in the Generic Drugs Battlefield $PRX $TEVA $ACT $MYL $NVS http://stk.ly/kB9i9C - View all 0 replies
-
MagicDiligence
Weekly roundup of stocks moving in and out of Magic Formula Investing $MANT $VRX $PRX others http://stk.ly/eQAh4P - View all 0 replies
-
MagicDiligence
Stocks moving in and out of Joel Greenblatt's Magic Formula Investing screens this week $MRVL $ADI $PRX others http://stk.ly/fTvWeZ - View all 0 replies
-
MagicDiligence
Par Pharmaceuticals $PRX new to MFI. Generic drugs will be huge over next 2 years. Great balance sheet too. - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
LATEST REPLIES